[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
April 27, 1994

Developing the Clinical Application of Genetic Diagnosis: The Role of NIDDK-Reply

Author Affiliations

Tucson, Ariz
Briarcliff Manor, NY

JAMA. 1994;271(16):1240. doi:10.1001/jama.1994.03510400026023

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


In Reply.  —While we appreciate the letter by Drs Fradkin and Gorden in elaborating the role of the NIDDK in CF carrier screening, we believe that our comments are not inaccurate. In our article, we clearly acknowledged the central role of the NIDDK in sponsoring the NIH workshop. Fradkin and Gorden have taken some of our statements out of context. We stated the following: "Despite the anticipation of CF carrier testing 15 years earlier, no mechanisms had been put in place to develop policy in a proactive manner. Thus, almost by default, ASHG was placed in the position of responding to the commercial interests of biotechnology companies and organizing an NIH workshop...."Fradkin and Gorden are correct that the ASHG did not "organize" the NIH workshop, but the ASHG's formative role is evidenced by the fact that the NIH workshop included the entire membership of the ASHG ad hoc committee

First Page Preview View Large
First page PDF preview
First page PDF preview